PARIS, France—Long remissions and “potential cures” were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers expressing the BRCA mutation who were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after initial therapy.
Two thirds of women were alive seven years later in the phase three SOLO1 trial of olaparib maintenance therapy compared with placebo. The lead author of the study, Paul DiSilvestro MD, Professor in the Department of Obstetrics & Gynecology and Director of the Program of Women’s Oncology at Women & Infants Hospital, Brown University in Providence Rhode Island, gives the details to the Audio Journal of Oncology’s Peter Goodwin.
